VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept
Proceedings of the National Academy of Sciences · 12.11.2024 · 121 (46)
DOI: 10.1073/pnas.2322759121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 05.11.2024. Verfasst von Deepti Sharma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287. Hauptthemen laut MEDLINE: Receptors, Vascular Endothelial Growth Factor, Angiopoietin-Like Protein 4, Retinal Pigment Epithelium, Vascular Endothelial Growth Factor A. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research to Prevent Blindness (RPB), NEI NIH HHS, State of Maryland (The State of Maryland).
Abstract (Originalsprache)
Neovascular age-related macular degeneration (nvAMD) is the leading cause of severe vision loss in the elderly in the developed world. While the introduction of therapies targeting vascular endothelial growth factor (VEGF) has provided the first opportunity to significantly improve vision in patients with nvAMD, many patients respond inadequately to current anti-VEGF therapies. It was recently demonstrated that expression of a second angiogenic mediator, angiopoietin-like 4 (ANGPTL4), synergizes with VEGF to promote choroidal neovascularization (CNV) in mice and correlates with reduced response to anti-VEGF therapy in patients with nvAMD. Here, we report that expression of ANGPTL4 in patients with nvAMD increases following treatment with anti-VEGF therapy and that this increase is dependent on accumulation of hypoxia-inducible factor (HIF)-1α in response to inhibition of VEGF/KDR signaling in the retinal pigment epithelium (RPE). We therefore explored HIF-1 inhibition with 32-134D, a recently developed pharmacologic HIF-inhibitor, for the treatment of nvAMD. 32-134D prevented the expression of both VEGF and ANGPTL4 and was at least as effective as aflibercept in treating CNV in mice. Moreover, by preventing the increase in HIF-1α accumulation in the RPE in response to anti-VEGF therapy, combining 32-134D with aflibercept was more effective than either drug alone for the treatment of CNV. Collectively, these results help explain why many patients with nvAMD respond inadequately to anti-VEGF therapy and suggest that the HIF inhibitor 32-134D will be an effective drug—alone or in combination with current anti-VEGF therapies—for the treatment of patients with this blinding disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
- Department of Ophthalmology, The Fourth Affiliated Hospital of China Medical University, Eye Hospital of China Medical University, Key Lens Research Laboratory of Liaoning Province, Shenyang 110005, China.
- Department of Oncology and Diagnostic Sciences, School of Dentistry, Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201.
- Armstrong Oxygen Biology Research Center, Vascular Program, Institute for Cell Engineering, Department of Vascular Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
- Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287.
- Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205.
ORCID-Profile: Deepti Sharma, Yu Qin, Aumreetam Dinabandhu, Shaima Salman, Gregg L Semenza
Förderung
- Research to Prevent Blindness (RPB)
- NEI NIH HHS
- State of Maryland (The State of Maryland)
- Branna and Irving Sisenwein Professorship
- HHS | NIH | National Eye Institute (NEI)
- Armstrong Family Foundation
Zitieren
APA
Sharma, D., Lau, E., Qin, Y., Jee, K., Rodrigues, M., Guo, C., Dinabandhu, A., McIntyre, E., Salman, S., Hwang, Y., Moshiri, A., Semenza, G. L., Montaner, S., & Sodhi, A. (2024). VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept. Proceedings of the National Academy of Sciences, 121(46). https://doi.org/10.1073/pnas.2322759121
Vancouver
Sharma D, Lau E, Qin Y, Jee K, Rodrigues M, Guo C, et al. VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept. Proceedings of the National Academy of Sciences. 2024;121(46). doi:10.1073/pnas.2322759121
BibTeX
@article{Sharma2024,
author = {Sharma, Deepti and Lau, Evan and Qin, Yu and Jee, Kathleen and Rodrigues, Murilo and Guo, Chuanyu and Dinabandhu, Aumreetam and McIntyre, Emma and Salman, Shaima and Hwang, Yousang and Moshiri, Ala and Semenza, Gregg L and Montaner, Silvia and Sodhi, Akrit},
title = {VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {46},
doi = {10.1073/pnas.2322759121}
}
EUVIMED